Financial Times US Healthcare and Life Sciences Conference on June 6, 2012
Jefferies 2012 Global Healthcare Conference on June 7, 2012
2012 BIO International Convention Orphan Disease Forum on June 19-20, 2012
CRANBURY, N.J., June 4, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, and members of the Amicus team will participate in three upcoming conferences in June.
Financial Times (FT) US Healthcare and Life Sciences Conference in New York, NY
Mr. Crowley will participate in a panel, "The Right Medicine for the Right Person at the Right Time – Delivering on the Potential and Promise of Personalized Medicine." The panel will be held during the Financial Times (FT) US Healthcare and Life Sciences Conference on Wednesday, June 6, 2012 at 3:00 p.m. ET in New York, NY. More information about this event can be found at http://www.ftconferences.com/ushc
Jefferies 2012 Global Healthcare Conference in New York, NY
Mr. Crowley will present a corporate overview during the Jefferies 2012 Global Healthcare Conference in New York, NY on Thursday, June 7, 2012 at 2:30 p.m. ET. A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
2012 BIO International Convention Orphan Disease Forum in Boston, MA
The 2012 Orphan Disease Forum will be held June 19-20, 2012 as part of the 2012 BIO International Convention in Boston, MA. The forum is co-organized by Centric Health Resources and the National Organization for Rare Disorders (NORD), and is hosted by the Biotechnology Industry Organization. Mr. Crowley and members of the Amicus team will speak at the following sessions:
Considerations for Novel Approval Pathways for Rare and Orphan Diseases
- Tuesday, June 19, 2012, 3:45 p.m. – 5:30 p.m. ET
- Amicus speaker: John F. Crowley, Chairman and CEO
- For more information please visit https://mybio.zerista.com/event/member/47384
Specialized Marketing & Sales: A Vision for Orphan and Targeted Therapies
- Wednesday, June 20, 2012, 8:30 a.m. – 9:45 a.m. ET
- Amicus speaker: Jayne Gershkowitz, Senior Director, Patient Advocacy & Public Policy
- For more information please visit https://mybio.zerista.com/event/member/46585
Is Big Pharma the Preferred Partner for Orphan Drug Biotechs?
- Wednesday, June 20, 2012, 2:00 p.m. - 3:30 p.m. ET
- Amicus speaker: Bradley Campbell, Chief Business Officer
- For more information please visit https://mybio.zerista.com/event/member/46587
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of diseases including lysosomal storage disorders and diseases of neurodegeneration. Amicus' lead program migalastat HCl is in Phase 3 for the treatment of Fabry disease.
FOLD-G